A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01
Status:
Terminated
Trial end date:
2016-11-09
Target enrollment:
Participant gender:
Summary
This 3-part study will explore the safety and tolerability of GLWL-01 in overweight/obese
healthy participants after single doses (in Part A), and in participants with type 2 diabetes
mellitus after multiple doses during a 28-day period (Parts B and C).